Cabaletta Bio, Inc. Banner Image

Cabaletta Bio, Inc.

  • Ticker CABA
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Cabaletta Bio, Inc. Logo Image
  • 51-200 Employees
  • Based in Philadelphia, Pennsylvania
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA) platform, in combination with Cabaletta’s proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectivelyMore bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company’s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ Phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the DesCAARTes™ Phase 1 clinical trial, please see www.clinicaltrials.gov. The Company’s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis.
4.8 / 5.0 (128)

Cabaletta Bio, Inc. reports have an aggregate usefulness score of 4.8 based on 128 reviews.

Cabaletta Bio, Inc.

Most Recent Annual Report

Cabaletta Bio, Inc.
MOST RECENT 2023 Annual Report and Form 10K

Older/Archived Annual Reports

Cabaletta Bio, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!